We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Opens the Door for Metadate ER Generics
FDA Opens the Door for Metadate ER Generics
July 3, 2013
The FDA has determined that UCB did not discontinue Metadate ER for safety and effectiveness reasons, paving the way for generic versions of the attention deficit/hyperactivity disorder (ADHD) drug.